Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| LENZ Therapeutics | 2024 | Post Ipo Equity | $30.0M | Del Mar |
| AM Batteries | 2024 | Grant | $2.2M | Chelmsford |
| Frontier Medicines | 2024 | Series C | $20.0M | San Francisco |
| Bright Peak Therapeutics | 2024 | Series C | $90.0M | Allschwil |
| Ajax Therapeutics | 2024 | Series C | $95.0M | Cambridge |
| Bluejay Therapeutics | 2024 | Series C | $182.0M | San Mateo |
| Obsidian Therapeutics | 2024 | Series C | $160.5M | Cambridge |
| SeLux Diagnostics | 2024 | Series D | $48.0M | Charlestown |
| CervoMed | 2024 | Post Ipo Debt | $149.4M | Boston |
| Stoke Therapeutics | 2024 | Post Ipo Equity | $125.0M | Bedford |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 326 | LENZ Therapeutics | Post Ipo Equity | $30.0M | Del Mar, United States |
| 327 | AM Batteries | Grant | $2.2M | Chelmsford, United States |
| 328 | Frontier Medicines | Series C | $20.0M | San Francisco, United States |
| 329 | Bright Peak Therapeutics | Series C | $90.0M | Allschwil, Switzerland |
| 330 | Ajax Therapeutics | Series C | $95.0M | Cambridge, United States |
| 331 | Bluejay Therapeutics | Series C | $182.0M | San Mateo, United States |
| 332 | Obsidian Therapeutics | Series C | $160.5M | Cambridge, United States |
| 333 | SeLux Diagnostics | Series D | $48.0M | Charlestown, United States |
| 334 | CervoMed | Post Ipo Debt | $149.4M | Boston, United States |
| 335 | Stoke Therapeutics | Post Ipo Equity | $125.0M | Bedford, United States |
LENZ Therapeutics operates as an organization engaged in the late-stage clinical development of pharmaceuticals for the eyes.
AM Batteries manufactures Li-ion batteries using solvent-free electrode manufacturing technology.
Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
SeLux Diagnostics is a developer of a next-generation phenotyping platform that provides personalized antimicrobial therapies to patients.
CervoMed a clinical-stage firm focused on discovering therapies for brain degenerative illnesses.
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.
Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.
NAPIGEN is a biotechnology company that addresses novel genome engineering of various organisms such as plants, microbes, and animals.
MMI is focused on advancing robotic technology for soft tissue open surgery with the world's smallest wristed instruments.
ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Tourmaline Bio is a biotechnology company that develops medicines to treat inflammatory and immune diseases in patients.
Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.
Forward Therapeutics is a biopharma comapny targeting treatment of chronic inflammatory disorders.
Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.
Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.
Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.
Ventricle Health offers evidence-based therapy, remote patient monitoring, patient education, and advocacy services for cardiac care.
Cerevel Therapeutics is a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric disorders.
Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.
Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins.
RA Capital Management has invested in 416 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 20 different industry categories.
Among tracked funding rounds, Cerevel Therapeutics received $450.0M in a Post Ipo Equity round. RA Capital Management's total known invested capital is $19.0B.
RA Capital Management's average investment size is $91.5M across its portfolio of 416 companies.
Recent RA Capital Management portfolio additions include LENZ Therapeutics, AM Batteries, Frontier Medicines, Bright Peak Therapeutics, Ajax Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors